Journal of Thoracic Oncology
The page or action you requested has resulted in an error. Please go back to the previous page by using your browser’s Back button, or visit the Home Page.
The page or action you requested has resulted in an error. Please go back to the previous page by using your browser’s Back button, or visit the Home Page.
Syria is a low-income country located on the eastern shores of the Mediterranean Sea basin in the Middle East. The area of Syria is 185,180…
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1)…
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1)…
Nature Reviews Clinical Oncology – ALND can be safely omitted for patients with sentinel-node macrometastases
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical…
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished.…
Nature Reviews Clinical Oncology – T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers…
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer…
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion,…